Please provide feedback on the files below Activity 1 Report and Decision Models 1 (decision tree) and 2 (continuum) by answering the following questions.
1. Regarding the drivers identified through literature review and key informant interviews:
a. In your opinion, are there additional drivers that were not identified?
b. Do the thematic labels/drivers categories adequately capture the listed enabling/hindering factors?
2. In your experience, what are some of the challenges for implementing managed entry agreements (MEAs)
that were not captured in the analysis? Please specify if challenges are related to high income or low-middle income countries.What are some interventions/tools that would help in addressing those challenges?
3. Two models (decision tree and continuum models) have been drafted to facilitate the dialogue between drug companies and payers about providing patients’ access to new drugs. What are your general impressions regarding the use and potential application of the model in low and middle-income settings?(note that a quantitative model to inform decision making is also under development and will be shared for feedback at a later time)
Discussion
Activity 1 Report & Models - Feedback Required!
Please provide feedback on the files below Activity 1 Report and Decision Models 1 (decision tree) and 2 (continuum) by answering the following questions.
1. Regarding the drivers identified through literature review and key informant interviews:
a. In your opinion, are there additional drivers that were not identified?
b. Do the thematic labels/drivers categories adequately capture the listed enabling/hindering factors?
2. In your experience, what are some of the challenges for implementing managed entry agreements (MEAs)
that were not captured in the analysis? Please specify if challenges are related to high income or low-middle income countries. What are some interventions/tools that would help in addressing those challenges?
3. Two models (decision tree and continuum models) have been drafted to facilitate the dialogue between drug companies and payers about providing patients’ access to new drugs. What are your general impressions regarding the use and potential application of the model in low and middle-income settings? (note that a quantitative model to inform decision making is also under development and will be shared for feedback at a later time)
Activity: Introduce Yourself
Welcome!
Please spend some time and introduce yourself to this multi-stakeholder online community by providing the following.
What is TRIPS?
What is TRIPS?